Philip E. Thorpe
University of Texas System
26 Papers
479 Citations
Philip E. Thorpe is an academic researcher from University of Texas System. The author has contributed to research in topics: Tissue factor & Phosphatidylserine. The author has an hindex of 9, co-authored 26 publications. Previous affiliations of Philip E. Thorpe include University of Texas at Austin & University of Texas at Dallas.
Chat about Author
Papers
Patent
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
Philip E. Thorpe,Francis J. Burrows +1 more
- 05 Mar 1993
TL;DR: In this paper, the authors present methods and compositions for targeting the vasculature of solid tumors using immunologically-based reagents, such as antibodies carrying diagnostic or therapeutic agents.
280
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Liesbeth M. Veenendaal,Hangqing Jin,Sophia Ran,Lawrence Cheung,Nora M. Navone,John W. Marks,Johannes Waltenberger,Philip E. Thorpe,Michael G. Rosenblum +8 more
TL;DR: These studies demonstrate the successful use of VEGF121/rGel fusion construct for the targeted destruction of tumor vasculature in vivo.
168
•Journal Article
Mechanistic studies of a novel, human fusion toxin composed of vascular endothelial growth factor (VEGF)121and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells
TL;DR: Delivery of the human proapoptotic pathway enzyme GrB to tumor vascular endothelial cells or to tumor cells may have significant therapeutic potential and represents a potent new class of targeted therapeutic agents with a unique mechanism of action.
48
Patent
Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
Philip E. Thorpe,Steven W. King,Boning Gao +2 more
- 20 Jan 1998
TL;DR: In this paper, the authors proposed methods and compositions comprising coagulation-deficient Tissue Factor (TF) for use in effecting specific coagulations and for using in tumor treatment.
27
Patent
Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
Philip E. Thorpe,Troy A. Luster,Steven W. King +2 more
- 24 Jan 2006
TL;DR: In this paper, new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof, have been presented for tumor vasculature targeting, cancer diagnosis and treatment.
23